Publications by authors named "M Aloulah"
Background: Endoscopic sinus surgery (ESS) has become the gold standard for treating patients with chronic rhinosinusitis (CRS) refractory to medical therapy. It is considered a relatively safe and effective procedure in all age groups, with overall success rates ranging from 76% to 97.5%.
View Article and Find Full Text PDFArticle Synopsis
- Chronic Rhinosinusitis (CRS) affects 5%-12% of people worldwide and is classified into type 2 and non-type 2 diseases, with type 2 inflammation marked by specific cytokines and immune cell activity.
- A retrospective study in Saudi Arabia assessed the prevalence of type 2 inflammation in patients with nasal polyps who underwent Endoscopic Sinus Surgery (ESS) from 2015 to 2020, focusing on factors like blood eosinophils and IgE levels.
- Results showed a striking 99.7% prevalence of type 2-CRS among the 381 studied patients, with significant rates of olfactory dysfunction and common co-morbidities like allergic rhinitis and asthma.
Maxillary sinus pathology is commonly approached through endoscopic middle meatal antrostomy (MMA). However, MMA does not provide full exposure to certain aspects of the maxillary sinus, such as alveolar, zygomatic, and prelacrimal recesses. In these hidden maxillary sinus niches, a combination approach with MMA is required for better exposure and access.
View Article and Find Full Text PDFInferior meatal antrostomy (IMA) is a safe and easy approach to the maxillary sinus. However, studies have shown disadvantages of conventional IMA, such as disruption of mucociliary transport and injury of the nasolacrimal duct (NLD). Endoscopic middle meatal antrostomy (MMA) has become the standard of care for addressing various maxillary pathologies.
View Article and Find Full Text PDFObjectives: To aimed to determine the incidence of complications of endoscopic sinus surgery (ESS) and to investigate the factors associated with the occurrence of complications.
Methods: In this retrospective study, we reviewed the medical records of all patients who had undergone ESS at King Saud University Medical City (KSUMC) between January 2015 and March 2022. Patients who underwent ESS for complicated acute sinusitis, sinonasal malignancy, and cerebrospinal fluid leak repair, and those who underwent extended ESS for indications other than chronic rhinosinusitis were excluded.